Current Edition

Anti-tuberculosis drug target discovery by targeting the higher in-degree proteins (HidPs) of the pathogen's transcriptional network

Tao Cui, Jumei Zeng, Zheng-Guo He*

    With the emergence of multiple-drug resistant bacteria pathogens, it has become increasingly important to develop new strategies for exploring alternative drug targets and new bactericides. However, new drug targets with a different antimycobacterial spectrum than current clinical drugs are lacking. In this study, based on a transcriptional regulation (TR) network of Mycobacterium tuberculosis, more than 60 higher in-degree proteins (HidPs) from the network were first characterized.

Unite to end TB

Zuber Ahmed*; Ishma Zubair

    Tuberculosis is one of the world's deadliest diseases and is a major global health problem. In 2016, there were an estimated 10.4 million new TB cases and an estimated 1.7 million TB deaths worldwide. The situation is further aggravated by emergence of MDR-TB and XDR-TB. In 2016, United Nations adopted a new set of goals, known as the Sustainable Development Goals (SDGs) to end TB. Ending TB by 2030 is a target of the SDGs and the goal of the End TB Strategy. WHO has set a target of 95% reduction in deaths and a 90% decline in TB incidence by 2035. WHO calls on all governments, communities, civil society, and the private sector to "Unite to End TB. Ending TB can be achieved with greater collaboration within and across governments.

Case study: Tuberculosis skin testing study tool

Cynthia Stone

    Tuberculosis continues to infect millions of people in the world each year and is the leading cause of death for people with HIV. Use of a Tuberculin Skin Test (TST) can be used to identify latent tuberculosis and to diagnose active tuberculosis disease. To assist in developing this skill a TST study tool was developed. The TST study tool has been used by various tuberculosis instructors in a mid-western state to meet the intent of providing skilled health care providers to do TST for patients entering long term care and employees in other health facilities.

Tuberculosis and tobacco smoking.

Jean Perriot*; Michel Underner; Gérard Peiffer

    Tuberculosis and tobacco smoking are two major public health problems which are causing a heavy mortality worldwide. Tobacco smoke increases the risks of Mycobacterium tuberculosis infection, of severe TB and death from TB. In emerging countries, quitting smoking is a means of controlling the TB epidemic. Smokers with TB are less compliant with TB medications, justifying smoking cessation support. Helping to quit smoking increases adherence to treatment of tuberculosis and tobacco abstinence rates among patients treated.

Leukopenia induced by anti-tuberculosis treatment

Belloumi Nidhal*; Ben Bdira Baraa; Bachouche Imene; Kacem Marwa; Chermiti Ben Abdallah Fatma; Fenniche Soraya

    Poor compliance to anti-tuberculosis treatment is sometimes related to its adverse effects. By reporting any unusual or severe treatment related accident, we try to enlarge our background in order to manage better any similar case.

Multifocal tuberculosis in Southern Tunisia: What is specific with?

Maroua Trigui; Houda Ben Ayed; Makram Koubaa; Maissa Ben Jemaa; Fatma Hammemi; Mariem Ben Hmida; Chokri Masmoudi; Chakib Marrakchi; Sourour Yaich; Jamel Damak; Mounir Ben Jemaa

    Objective: Tuberculosis (TB) is a public health concern worldwide. Multifocal Tuberculosis (MFT) is a severe disease and relatively an unusual form of TB. We aimed to identify the epidemiological and evolutionary characteristics of MFT in Southern Tunisia and to analyse its chronological trends between 1995 and 2016. Methods: We conducted a retrospective study from January 1995 to December 2016 in South of Tunisia including all new TB cases. MFT was defined as concurrent tubercular involvement of two or more non-contiguous organs.

MedDocs Publishers

We always work towards offering the best to you. For any queries, please feel free to get in touch with us. Also you may post your valuable feedback after reading our journals, ebooks and after visiting our conferences.